VIP inhibits human HepG2 cell proliferation in vitro

Regulatory Peptides

Volumn 146, Issue 1-3, 2008, Pages 285-292

  Absood, Afaf ^a   Hu, Bin ^a   Bassily, Nermine ^a   Colletti, Lisa ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Hepatocellular carcinoma; Hepatocyte proliferation; HGF; IL 6; VIP

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; CYCLIC AMP; INTERLEUKIN 6; SCATTER FACTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 38349049466     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.11.002     Document Type: Article

References (41)

1. Steel J., Carney M., Carr B.I., and Baum A. The role of psychosocial factors in the progression of hepatocellular carcinoma. Med Hypotheses 62 1 (2004) 86-94
2. Salem R., Thurston K.G., Carr B.I., Goin J.E., and Geschwind J.F.H. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13 9 (2002) S223-S229
3. Kelekis N.L., Semelka R.C., Worawattanakul S., de Lange E.E., Ascher S.M., Ahn I.O., et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on TI-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 170 4 (1998) 1005-1013
4. Casillas V.J., Amendola M.A., Gascue A., Pinnar N., Levi J.U., and Perez J.M. Imaging of nontraumatic hemorrhagic hepatic lesions. Radiographics 20 2 (2000) 367-378
5. Latchman D.S., and Stephanou A. STAT-I and STAT-3: closely related transcription factors with antagonistic effects on cell proliferation and apoptosis. Current Genomics 5 5 (2004) 453-457
6. Jing N., and Tweardy D.J. Targeting STAT-3 in cancer therapy. Anticancer Drugs 16 6 (2005) 601-607
7. Jing N., Li Y.D., Xu X.J., Sha W., Li P., Feng L.L., and Tweardy D.J. Targeting STAT-3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 22 II (2003) 685-696
8. Nikitakis N.G., Siavash H., and Sauk J.J. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets 4 8 (2004) 637-651
9. Brender C., Lovato P., Sommer V.H., Woetmann A., Mathiesen A.M., Geisler C., Wasik M., and Odum N. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFN alpha. Leukemia 19 2 (2005) 209-213
10. Christine R., Sylvie R., Erik B., Genevieve P., Amelie R., Gerard R., Marc B., Christian G., and Samir A. Implication of STAT-3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Research 65 I (2005) 195-202
11. Sun J.Z., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S.D.M. Cucurbitacin Q: a selective STAT-3 activation inhibitor with potent antitumor activity. Oncogene 24 20 (2005) 3236-3245
12. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., Hippe F., Vatter S., Merz K.H., Eisenbrand G., and Jove R. Indirubin derivatives inhibit STAT-3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 102 I7 (2005) 5998-6003
13. Dauer D.J., Ferraro B., Song L.X., Yu B., Mora L., Buettner R., Enkemann S., Jove R., and Haura E.B. STAT-3 regulates genes common to both wound healing and cancer. Oncogene 24 21 (2005) 3397-3408
14. Turkson J., Zhang S.M., Palmer J., Kay H., Stanko J., Mora L.B., Sebti S., Yu H., and Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3 12 (2004) 1533-I542
15. Coskun U., Bukan N., Sancak B., Gunel N., Ozenirler S., Unal A., and Yucel A. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51 3 (2004) 209-213
16. Sun J.Z., Wang D.A., Jain R.K., Carie A., Paquette S., Ennis E., Blaskovich M.A., Baldini L., Coppola D., Hamilton A.D., and Sebti S.M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24 29 (2005) 4701-4709
17. Anton P.A., Shanahan F., Sun X.P., Diehl D., Kodner A., and Mayer E.A. Vip modulates intracellular calcium oscillations in human lymphoblasts. Immunopharmacol Immunotoxicol 15 4 (1993) 429-446
18. Vertongen P., Camby I., Darro F., Kiss R., and Robberecht P. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides 30 5 (1996) 491-496
19. Delgado M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276 1 (2001) 369-380
20. Tuncel N., Tore F., Sahinturk V., Ak D., and Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 21 1 (2000) 81-89
21. Tuncel N., and Tore F.C. The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide synthase on survival rate in rats exposed to endotoxin shock. Vip, Pacap, and Related Peptides vol. 865 (1998) 586-589
22. Hanzawa M., Shindoh M., Higashino F., Yasuda M., Inoue N., Hida K., Ono M., Kohgo T., Nakamura M., Notani K., Fukuda H., Totsuka Y., Yoshida K., and Fujinaga K. Hepatocyte growth factor upregulates EIAF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 21 6 (2000) 1079-1085
23. To Y., Dohi M., Matsumoto K., Tanaka R., Sato A., Nakagome K., Nakamura T., and Yamamoto K. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol 27 2 (2002) 220-226
24. Matsumoto H., Koyama C., Sawada T., Koike K., Hirota K., Miyake A., Arimura A., and Inoue K. Pituitary folliculo-stellate-like cell-line (Ttt Gf) responds to novel hypophysiotropic peptide (pituitary adenylate cyclase-activating peptide), showing increased adenosine-3',5'-monophosphate and interleukin-6 secretion and cell-proliferation. Endocrinology 133 5 (1993) 2150-2155
25. Sundelin K., Roberg K., Grenman R., and Hakansson L. Effects of cytokines on matrix metalloproteinase expression in oral squamous cell carcinoma in vitro. Acta Otolaryngol 125 7 (2005) 765-773
26. Knight B., Matthews V.B., Akhurst B., Croager E.J., Klinken E., Abraham L.J., Olynyk J.K., and Yeoh G. Liver inflammation and cytokine production,but not acute phase protein synthesis, accompany the adult liverprogenitor (oval) cell response to chronic liver injury. Immunol Cell Biol 83 4 (2005) 364-374
27. Neaud V., Faouzi S., Guirouilh J., LeBail B., Balabaud C., BioulacSage P., and Rosenbaum J. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology. 26 6 (1997) 1458-1466
28. Syed V., Ulinski G., Mok S.C., and Ho S.M. Reproductive hormone-induced, STAT-3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 94 8 (2002) 617-629
29. Absood A, Furutani A, Kawamura T, Graham LM. Differential PDGF secretion by graft and aortic SMC in response to oxidized LDL. Am J Physiol, Heart Circ Physiol 283(2): H725-H732, 2002.
30. Lutz E.M., MacKenzie C.J., Johnson M., West K., Morrow J.A., Harmar A.J., and Mitchell R. Domains determining agonist selectivity in chimaeric VIP2 (VPAC(2))/PACAP (PAC(1)) receptors. Br J Pharmacol 128 4 (1999) 934-940
31. Kojima M., Ito T., Oono T., Hisano T., Igarashi H., Arita Y., Kawabe K., Coy D.H., Jensen R.T., and Nawata H. VIP attenuation of the severity of experimental pancreatitis is due to VPAC(1) receptor-mediated inhibition of cytokine production. Pancreas 30 1 (2005) 62-70
32. Filippatos G.S., Gangopadhyay N., Lalude O., Parameswaran N., Said S.I., Spielman W., and Uhal B.D. Regulation of apoptosis by vasoactive peptides. Am J Physiol, Lung Cell Mol Physiol 281 4 (2001) L749-L761
33. Namekata K., Takamori S., Kojima K., Beppu T., and Futagawa S. Significant changes in the serum levels of IL-6, h-HGF, and type IV collagen 7S during the perioperative period of a hepatectomy: relevance to SIRS. Surg Today 30 5 (2000) 403-409
34. Guirouilh J., Le Bail B., Boussarie L., Balabaud C., Bioulac-Sage P., Desmouliere A., Schuppan D., and Rosenbaum J. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 34 1 (2001) 78-83
35. Maruno K., Absood A., and Said S.I. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. Proc Natl Acad Sci U S A 95 24 (1998) 14373-14378
36. Yin Y., Allen P.D., Jia L., MacEy M.G., Kelsey S.M., and Newland A.C. Constitutive levels of cAMP-dependent protein kinase activity determine sensitivity of human multidrug-resistant leukaemic cell lines to growth inhibition and apoptosis by forskolin and tumour necrosis factor alpha. Br J Haematol 108 3 (2000) 565-573
37. Ollivier V., Parry G.C.N., Cobb R.R., deProst D., and Mackman N. Elevated cyclic AMP inhibits NF-kappa B-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271 34 (1996) 20828-20835
38. Lee J., Choi Y.H., Nguyen P.M., Kim J.S., Lee S.J., and Trepel J.B. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim Biophys Acta 1449 3 (1999) 261-268
39. Takanaga H, Yoshitake T, Hara S, Yamasaki C, Kunimoto M. cAMP-induced astrocytic differentiation of C6 glioma cells is mediated by autocrine interleukin-6. J Biol Chem 279(15): 15441-15447, 2004.
40. Liu AMF, Lo RKH, Wong CSS, Morris C, Wise H, Wong Y.H. Activation of STAT-3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J Biol Chem 281(47): 35812-35825, 2006.
41. Lee J, Choi YH, Nguyen PM, Kim JS, Lee SJ, Trepel JB. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochem Biophys Acta 1449(3): 261-268, 1999.